ImmunityBio
IBRX
IBRX
130 hedge funds and large institutions have $84.1M invested in ImmunityBio in 2023 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less call options, than puts
Call options by funds: $ | Put options by funds: $
1.5% less ownership
Funds ownership: 8.97% → 7.47% (-1.5%)
23% less capital invested
Capital invested by funds: $109M → $84.1M (-$24.6M)
Holders
130
Holding in Top 10
–
Calls
$4.51M
Puts
$4.7M
Top Buyers
| 1 | +$7.34M | |
| 2 | +$5.87M | |
| 3 | +$2.22M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$875K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$755K |
Top Sellers
| 1 | -$566K | |
| 2 | -$537K | |
| 3 | -$408K | |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$147K |
| 5 |
State Street
Boston,
Massachusetts
|
-$97.4K |